Small-Cell Lung Cancer-An Update on Targeted and Immunotherapies.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
01 May 2023
Historique:
received: 02 04 2023
revised: 23 04 2023
accepted: 29 04 2023
medline: 15 5 2023
pubmed: 13 5 2023
entrez: 13 5 2023
Statut: epublish

Résumé

Small-cell lung cancer (SCLC) is an aggressive disease with distinct biological and clinical features. The clinical course of SCLC is generally characterised by initial sensitivity to DNA-damaging therapies, followed by early relapse and broad cross resistance to second line agents. Whilst there has been an enormous expansion of effective targeted and immune-based therapeutic options for non-small cell lung cancer (NSCLC) in the last decade, little improvement has been achieved in SCLC treatment and survival due, at least in part, to underappreciated inter- and intra-tumoral heterogeneity. Here we review the current treatment paradigm of SCLC including recent advances made in utilizing immunotherapy and the challenges of identifying a predictive biomarker for immunotherapy response. We examine emerging new targeted therapies, combination immunotherapy and future directions of SCLC treatment research.

Identifiants

pubmed: 37175833
pii: ijms24098129
doi: 10.3390/ijms24098129
pmc: PMC10179261
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Clin Cancer Res. 2021 May 1;27(9):2378-2382
pubmed: 33288660
N Engl J Med. 2022 Mar 24;386(12):1143-1154
pubmed: 35320644
Cancer Discov. 2019 May;9(5):646-661
pubmed: 30777870
Clin Cancer Res. 2008 Oct 1;14(19):6092-6
pubmed: 18829487
J Clin Oncol. 2021 Feb 20;39(6):619-630
pubmed: 33439693
Medicine (Baltimore). 2017 Mar;96(13):e6412
pubmed: 28353568
Cancers (Basel). 2021 Feb 10;13(4):
pubmed: 33578789
Lancet Oncol. 2022 Jun;23(6):739-747
pubmed: 35576956
J Clin Oncol. 2012 May 10;30(14):1692-8
pubmed: 22473169
Eur J Cancer. 2003 Apr;39(6):793-9
pubmed: 12651205
Semin Oncol. 1994 Jun;21(3 Suppl 6):23-30
pubmed: 8052870
J Clin Oncol. 2006 Dec 1;24(34):5441-7
pubmed: 17135646
Cancer Cell. 2021 Mar 8;39(3):346-360.e7
pubmed: 33482121
J Thorac Oncol. 2021 Sep;16(9):1582-1588
pubmed: 34242790
J Clin Oncol. 2016 Apr 1;34(10):1057-64
pubmed: 26786925
J Thorac Oncol. 2021 Sep;16(9):1429-1433
pubmed: 34425994
Ann Oncol. 1994 Sep;5(7):601-7
pubmed: 7993835
N Engl J Med. 2019 Mar 7;380(10):989-990
pubmed: 30855760
Nat Genet. 2012 Oct;44(10):1111-6
pubmed: 22941189
Sci Transl Med. 2015 Aug 26;7(302):302ra136
pubmed: 26311731
Immunol Cell Biol. 2015 Mar;93(3):290-6
pubmed: 25367186
J Clin Oncol. 2018 Aug 10;36(23):2386-2394
pubmed: 29906251
Clin Cancer Res. 2017 Jan 15;23(2):523-535
pubmed: 27440269
Clin Cancer Res. 2017 Oct 1;23(19):5711-5719
pubmed: 28679770
Cancer Sci. 2016 Jul;107(7):1039-46
pubmed: 27166974
J Natl Cancer Inst. 1991 Jun 19;83(12):855-61
pubmed: 1648142
Ann Oncol. 2011 Sep;22(9):1973-1980
pubmed: 21727198
J Thorac Oncol. 2019 Aug;14(8):1447-1457
pubmed: 31063862
Transl Lung Cancer Res. 2022 May;11(5):832-844
pubmed: 35693282
Ann Transl Med. 2021 Aug;9(16):1285
pubmed: 34532422
J Thorac Oncol. 2021 Sep;16(9):1559-1569
pubmed: 33652156
Cancer Lett. 2009 Oct 8;283(2):203-11
pubmed: 19394761
J Thorac Oncol. 2021 Sep;16(9):1547-1558
pubmed: 33607312
Lung Cancer. 2002 Sep;37(3):271-6
pubmed: 12234695
Clin Cancer Res. 2021 Mar 1;27(5):1526-1537
pubmed: 33203642
J Thorac Oncol. 2020 Apr;15(4):618-627
pubmed: 31870883
J Clin Oncol. 2023 Jun 1;41(16):2893-2903
pubmed: 36689692
Lancet Oncol. 2020 Sep;21(9):1224-1233
pubmed: 32888454
Nat Rev Cancer. 2017 Dec;17(12):725-737
pubmed: 29077690
J Cancer Res Clin Oncol. 2022 Oct;148(10):2661-2671
pubmed: 34748028
JAMA. 2022 Sep 27;328(12):1223-1232
pubmed: 36166026
Nature. 1992 Mar 26;356(6367):356-8
pubmed: 1549180
J Thorac Oncol. 2021 Sep;16(9):1570-1581
pubmed: 33823285
Cancer Discov. 2019 Oct;9(10):1372-1387
pubmed: 31416802
J Clin Oncol. 2020 Jul 20;38(21):2369-2379
pubmed: 32468956
J Thorac Oncol. 2018 Jan;13(1):112-123
pubmed: 28951314
Future Oncol. 2019 Jan;15(3):231-239
pubmed: 30362375
J Clin Oncol. 2006 Oct 1;24(28):4539-44
pubmed: 17008692
J Clin Oncol. 1999 Feb;17(2):658-67
pubmed: 10080612
Clin Lung Cancer. 2020 Mar;21(2):e84-e88
pubmed: 31948903
Lancet. 2019 Nov 23;394(10212):1929-1939
pubmed: 31590988
Cancer. 2004 Feb 15;100(4):801-6
pubmed: 14770437
Cancer Treat Res Commun. 2021;28:100405
pubmed: 34329846
Oncotarget. 2017 Apr 25;8(17):28575-28587
pubmed: 28212573
Lancet Oncol. 2020 May;21(5):645-654
pubmed: 32224306
N Engl J Med. 2019 Feb 14;380(7):617-628
pubmed: 30516102
Lancet Respir Med. 2023 Jan;11(1):74-86
pubmed: 36252599
J Thorac Oncol. 2010 Aug;5(8):1279-84
pubmed: 20559150
Nature. 2015 Aug 6;524(7563):47-53
pubmed: 26168399
Lung Cancer. 2014 Nov;86(2):237-40
pubmed: 25194640
J Thorac Oncol. 2010 Nov;5(11):1835-40
pubmed: 20881645
Expert Opin Biol Ther. 2019 May;19(5):423-432
pubmed: 30855195
Arch Pathol Lab Med. 2019 Nov;143(11):1373-1377
pubmed: 30958693
N Engl J Med. 1992 Dec 3;327(23):1618-24
pubmed: 1331787
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Cancer. 2005 May 15;103(10):2128-31
pubmed: 15812822
Transl Lung Cancer Res. 2022 Jun;11(6):1069-1078
pubmed: 35832454
Future Oncol. 2022 Jun;18(19):2351-2360
pubmed: 35510484
Lancet Oncol. 2021 Jan;22(1):51-65
pubmed: 33285097
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
Clin Cancer Res. 2014 Feb 1;20(3):631-43
pubmed: 24240111
Br J Cancer. 2017 Jun 27;117(1):8-14
pubmed: 28510571
Cancer Cell. 2018 May 14;33(5):853-861.e4
pubmed: 29731394
J Thorac Oncol. 2019 Feb;14(2):237-244
pubmed: 30316010
J Clin Oncol. 2015 May 20;33(15):1660-5
pubmed: 25732163
J Clin Oncol. 2021 Apr 20;39(12):1349-1359
pubmed: 33683919
Clin Breast Cancer. 2011 Oct;11(5):275-82
pubmed: 21729661
N Engl J Med. 2021 Apr 22;384(16):1529-1541
pubmed: 33882206
J Thorac Dis. 2017 Mar;9(3):E285-E289
pubmed: 28449522
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
Ann Oncol. 2021 May;32(5):631-641
pubmed: 33539946
Lung Cancer. 2006 Apr;52(1):93-7
pubmed: 16488055
Lung Cancer. 2017 Jul;109:78-88
pubmed: 28577955
Lancet Oncol. 2017 Jan;18(1):42-51
pubmed: 27932068

Auteurs

Nicholas McNamee (N)

Blacktown and Westmead Hospitals, Sydney, NSW 2145, Australia.

Ines Pires da Silva (IP)

Blacktown and Westmead Hospitals, Sydney, NSW 2145, Australia.
Westmead Clinical School, University of Sydney, Sydney, NSW 2145, Australia.

Adnan Nagrial (A)

Blacktown and Westmead Hospitals, Sydney, NSW 2145, Australia.
Westmead Clinical School, University of Sydney, Sydney, NSW 2145, Australia.

Bo Gao (B)

Blacktown and Westmead Hospitals, Sydney, NSW 2145, Australia.
Westmead Clinical School, University of Sydney, Sydney, NSW 2145, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH